Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivorsXinyu Liu, Jingnan Li, Bo Lü et al.|EBioMedicine|2024Cited by 40
Risk of malignancy in patients with inflammatory bowel disease: A population‐based cohort study from ChinaHuimin Zhang, Jiaming Qian, Yue Li et al.|International Journal of Cancer|2022Cited by 20
A Concerning Case of Severe Gastritis With Gastrointestinal Protein LossXinyu Liu, Bei Tan, Hao Tang|Gastroenterology|2024Cited by 0